Genomic Vision announces the acceptance notice of the second tranche of €1.0 million within the framework of the equity financing put in place with Winance

Bagneux (France) - Genomic Vision (FR0011799907 – GV), a company specialized in the development of in-vitro diagnostic (IVD) tests for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), announces that it has today initiated the process of issuing 10,000,000 new shares at a unit price of €0.10, corresponding to a capital increase of €1.0 million, within the framework of the financing contract signed with Winance in accordance with the approval granted by the Company's shareholders at the EGM of March 4, 2019.

Following this operation, the share capital of Genomic Vision will consist of 33,474,390 shares. The new shares will be freely tradable and immediately assimilated to the existing ordinary shares listed on the Euronext market in Paris.

The main characteristics of this financing, comprising 4 tranches of shares with equity warrants attached (ABSAs) for a total of €5 million, are described in the Prospectus granted visa number 19-122 by the AMF French stock market authority on March 29, 2019 comprising a Note d'opération and a Document de référence filed with the AMF under reference number R19-004.

***

ABOUT GENOMIC VISION

GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing to identify genetic abnormalities, GENOMIC VISION stimulates the R&D productivity of the pharmaceutical companies, the leaders of the diagnostic industry and the research labs. The Company develops a robust portfolio of diagnostic tests (breast, ovarian and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based near Paris, in Bagneux, the Company has approximately 40 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV - ISIN: FR0011799907). For further information, please visit www.genomicvision.com
ABOUT WINANCE

Winance is a global equity investor in SMEs that have a unique competitive advantage and a capacity to deliver short and long-term growth, in order to enable these companies to finance themselves competitively for growth and/or working capital needs.

Website: www.winance.com

CONTACTS

Genomic Vision
Aaron Bensimon
Co-founder, Chairman & CEO
Tel.: +33 1 49 08 07 50
investisseurs@genomicvision.com

Ulysse Communication
Bruno Arabian
Press Relations
Tel.: +33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor Relations & Strategic Communications
Tel.: +33 1 44 71 94 94
gv@newcap.eu

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the reference document filed with the AMF under reference number R19-004 on March 29, 2019, available on the website of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.